Clinical trial
Sema 4A as a Marker for Inflammatory Disease in Multiple Sclerosis
NCT05077956
Study timeline
Study start (actual)2021-10-19Date precision: day
Registry last updated2023-08-07
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Relapsing Multiple Sclerosisunresolved
Multiple Sclerosisunresolved
Interventions
Cerebrospinal and Blood Serum Semaphorin 4A LevelsDIAGNOSTIC_TEST
Sponsors & collaborators
Providence Health & Serviceslead sponsor
Milton S. Hershey Medical Centercollaborator
Bristol-Myers Squibbcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05077956 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.